Literature DB >> 27325646

Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines.

Sheng Guo1, Wubin Qian1, Jie Cai1, Likun Zhang1, Jean-Pierre Wery1, Qi-Xiang Li2.   

Abstract

The Cancer Genome Atlas (TCGA) project has generated abundant genomic data for human cancers of various histopathology types and enabled exploring cancer molecular pathology per big data approach. We developed a new algorithm based on most differentially expressed genes (DEG) per pairwise comparisons to calculate correlation coefficients to be used to quantify similarity within and between cancer types. We systematically compared TCGA cancers, demonstrating high correlation within types and low correlation between types, thus establishing molecular specificity of cancer types and an alternative diagnostic method largely equivalent to histopathology. Different coefficients for different cancers in study may reveal that the degree of the within-type homogeneity varies by cancer types. We also performed the same calculation using the TCGA-derived DEGs on patient-derived xenografts (PDX) of different histopathology types corresponding to the TCGA types, as well as on cancer cell lines. We, for the first time, demonstrated highly similar patterns for within- and between-type correlation between PDXs and patient samples in a systematic study, confirming the high relevance of PDXs as surrogate experimental models for human diseases. In contrast, cancer cell lines have drastically reduced expression similarity to both PDXs and patient samples. The studies also revealed high similarity between some types, for example, LUSC and HNSCC, but low similarity between certain subtypes, for example, LUAD and LUSC. Our newly developed algorithm seems to be a practical diagnostic method to classify and reclassify a disease, either human or xenograft, with better accuracy than traditional histopathology. Cancer Res; 76(16); 4619-26. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27325646     DOI: 10.1158/0008-5472.CAN-15-3245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.

Authors:  Mara Gilardi; Zhiyong Wang; Marco Proietto; Anastasia Chillà; Juan Luis Calleja-Valera; Yusuke Goto; Marco Vanoni; Matthew R Janes; Zbigniew Mikulski; Antonio Gualberto; Alfredo A Molinolo; Napoleone Ferrara; J Silvio Gutkind; Francis Burrows
Journal:  Mol Cancer Ther       Date:  2020-07-29       Impact factor: 6.261

2.  Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.

Authors:  Chang Shu; Qiong Wang; Xiaoling Yan; Jinhuan Wang
Journal:  J Mol Neurosci       Date:  2018-03-03       Impact factor: 3.444

3.  A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.

Authors:  Hanting Zhu; Chunyu Wang; Jingjing Wang; Dawei Chen; Jiaying Deng; Jianyun Deng; Jianhong Fan; Harun Badakhshi; Xuesong Huang; Likun Zhang; Jie Cai; Sheng Guo; Wubin Qian; Yongzhan Nie; Qixiang Li; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics.

Authors:  Christopher H Hulton; Emily A Costa; Nisargbhai S Shah; Alvaro Quintanal-Villalonga; Glenn Heller; Elisa de Stanchina; Charles M Rudin; John T Poirier
Journal:  Nat Cancer       Date:  2020-03-09

5.  BAG3 induces α-SMA expression in human fibroblasts and its over-expression correlates with poorer survival in fibrotic cancer patients.

Authors:  Margot De Marco; Nicoletta Del Papa; Francesca Reppucci; Vittoria Iorio; Anna Basile; Antonia Falco; Roberta Iaccarino; Sergio Brongo; Francesco De Caro; Mario Capunzo; Maria Caterina Turco; Alessandra Rosati; Liberato Marzullo
Journal:  J Cell Biochem       Date:  2021-11-06       Impact factor: 4.480

6.  Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.

Authors:  Wen-Hsin Liu; Paulina Mrozek-Gorska; Anna-Katharina Wirth; Tobias Herold; Larissa Schwarzkopf; Dagmar Pich; Kerstin Völse; M Camila Melo-Narváez; Michela Carlet; Wolfgang Hammerschmidt; Irmela Jeremias
Journal:  Biomark Res       Date:  2020-09-16

7.  Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity.

Authors:  Katie M Campbell; Tianxiang Lin; Paul Zolkind; Erica K Barnell; Zachary L Skidmore; Ashley E Winkler; Jonathan H Law; Elaine R Mardis; Lukas D Wartman; Douglas R Adkins; Rebecca D Chernock; Malachi Griffith; Ravindra Uppaluri; Obi L Griffith
Journal:  Cell Rep       Date:  2018-08-21       Impact factor: 9.423

8.  Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.

Authors:  Ying Jin; Xiaoyu An; Binchen Mao; Ruilin Sun; Rajendra Kumari; Xiaobo Chen; Yongli Shan; Mingfa Zang; Ling Xu; Jan Muntel; Kristina Beeler; Roland Bruderer; Lukas Reiter; Sheng Guo; Demin Zhou; Qi-Xiang Li; Xuesong Ouyang
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

9.  Murine Endogenous Retroviruses Are Detectable in Patient-Derived Xenografts but Not in Patient-Individual Cell Lines of Human Colorectal Cancer.

Authors:  Stephanie Bock; Christina S Mullins; Ernst Klar; Philippe Pérot; Claudia Maletzki; Michael Linnebacher
Journal:  Front Microbiol       Date:  2018-04-24       Impact factor: 5.640

10.  An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.

Authors:  Wai Hoong Chang; Alvina G Lai
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.